Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
13,122 total articles
Olesen Value Fund L.P., a major stakeholder in Solitron Devices Inc. (NASDAQ:SODI), executed a divestment of common stock valued at $361,181. The transactions took place on July 8 and July 10, 2026, reducing the fund's direct and indirect holdings in the semiconductor and related devices manufacturer. This sale occurs after a significant price appr…
Nuvalent, Inc. Chief Scientific Officer Henry E. Pelish sold 2,111 shares of the company's Class A Common Stock on July 9, 2026, generating $261,362 from the transaction. The sale was conducted under a Rule 10b5-1 plan established in December 2023, a mechanism typically used to manage tax obligations tied to equity vesting. Following the transactio…
Joseph Sanborn, serving as both Chief Financial Officer and Chief Administrative Officer at EverQuote, Inc. (NASDAQ: EVER), has executed a transaction to sell 6,667 shares of the company's Class A Common Stock. The sale, which generated proceeds totaling $164,208, was conducted on July 8, 2026. The transaction was facilitated through a Rule 10b5-1 …
Tracy G. Smith, Optical Cable Corp (NASDAQ:OCC) Executive Vice President and Chief Financial Officer, executed a series of stock sales totaling $284,189 across two distinct dates in late June and early July 2026. The transactions occur against a backdrop of recent corporate developments, including a significant fiscal second-quarter 2026 earnings t…
Christopher Van Tuyl, Chief Legal Officer at Immunovant, Inc. (NASDAQ:IMVT), executed a series of mandatory stock sales on July 8, 2026, to satisfy tax withholding requirements associated with restricted stock unit settlements. The transactions, totaling $47,702, involved the liquidation of 1,206 shares at prices closely tracking the stock's curren…
Jay S Stout, Chief Technology Officer at Immunovant, Inc., executed a mandatory sale of 3,487 shares on July 8, 2026, to satisfy tax withholding requirements tied to vesting restricted stock units. The transaction occurred as Immunovant's equity approached its 52-week peak, following a significant 135% annual gain. While the sale reduces direct own…
Tempus AI, Inc. (NASDAQ: TEM) CEO of Data, Ryan Fukushima, executed a $1.91 million sale of Class A Common Stock through his spouse on July 8, 2026, as part of a Rule 10b5-1 trading plan established in March 2025. The transaction involved 33,284 shares sold at weighted average prices between $56.80 and $59.47. This divestment follows a period of si…
JFrog Ltd (NASDAQ:FROG) Chief Executive Officer Shlomi Ben Haim executed a sale of 15,000 ordinary shares on July 8, 2026, generating approximately $1,415,525 in proceeds. The transaction was facilitated through a Rule 10b5-1 trading plan established earlier in the year. This sale follows a substantial 135% surge in JFrog's share price over the pas…
Immunovant Inc. (NASDAQ: IMVT) Chief Operating Officer Melanie Gloria executed a series of share sales totaling $80,531 on July 8, 2026. The transactions, driven by mandatory tax withholding requirements for vesting restricted stock units, occurred as the company's stock trades near its 52-week high. This executive activity unfolds against a backdr…
Ryan Cohlhepp, President and COO of Bicara Therapeutics Inc. (NASDAQ: BCAX), executed a series of stock sales totaling approximately $833,129 under a pre-arranged trading plan. The transactions, which followed the exercise of stock options, occurred on July 8 and July 9, 2026, as shares traded near their 52-week high. Concurrently, the biotech firm…
Bicara Therapeutics Inc. (NASDAQ:BCAX) Chief Financial Officer Hyep Ivan completed a significant stock sale on July 8, 2026, while simultaneously acquiring shares through option exercises. The transaction coincides with the company's ongoing clinical development of ficerafusp alfa for head and neck and colorectal cancers, alongside sustained analys…
Powell Industries Inc. (NASDAQ:POWL) President and Chief Executive Officer Brett Cope sold 4,440 shares of the company's common stock on July 9, 2026, realizing approximately $1,072,482 from the transaction. The sale was executed at a price of $241.55 per share pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2025. This transaction oc…
Kelly E. Garcia, Domino's Pizza Inc.'s Executive Vice President and Chief Technology & Data Officer, executed a significant equity transaction on July 9, 2026, selling 487 shares of the company's common stock. The sale, totaling $144,643, was conducted under a Rule 10b5-1 trading plan adopted in May 2025. This disposition followed the same-day exer…
Asaf Silberstein, Executive Vice President and Chief Operating Officer at Semtech Corp (NASDAQ:SMTC), executed a sale of company common stock valued at $1,086,318 on July 8, 2026. The transactions, processed through a Family Trust, involved 8,500 shares traded between $124.1895 and $129.9426 per share. These sales were conducted under a Rule 10b5-1…
MetLife Investment Management, LLC has executed a significant acquisition of debt securities issued by Angel Oak Financial Strategies Income Term Trust (NYSE:FINS). Acting as an investment manager for its clients, MetLife acquired 40,000,000 units of the trust's 5.364% Series C Senior Unsecured Notes due July 8, 2030. The transaction, finalized on …
Gary C. Bhojwani, a director at Hormel Foods Corp. (NASDAQ:HRL), executed a significant share sale on July 8, 2026, totaling $495,158. This transaction follows the company's recent second-quarter fiscal 2026 earnings report, which exceeded analyst expectations for both earnings per share and revenue. The move occurs as Hormel Foods continues to adj…
Tappan Moore III, Chief Operating Officer of Mama’s Creations, Inc. (NASDAQ:MAMA), sold 472 shares on July 8, 2026, for $8,801 at $18.648 per share to cover tax withholding on vested restricted stock units. Post-sale, he holds 12,869 shares. The company recently reported Q1 FY2027 earnings of $0.05 per share and $52.8 million in revenue, beating es…
William Lewis, Chair and Chief Executive Officer of INSMED Inc. (NASDAQ:INSM), executed a series of transactions on July 9, 2026, involving the sale of company shares and the exercise of stock options. The transactions were conducted under a Rule 10b5-1 trading plan established in September 2025. Concurrently, Insmed has announced key leadership ap…
United Therapeutics Corp (NASDAQ:UTHR) director Jan Malcolm sold 325 shares of common stock on July 10, 2026, for a total value of $178,941. The transaction was executed under a pre-arranged 10b5-1 plan established in September 2025. This sale comes amid significant corporate developments, including FDA approval for the LungFX device and positive p…
Allison M. Wing, a director at Casey’s General Stores Inc. (NASDAQ:CASY), executed a sale of 530 common shares on July 8, 2026, at a price of $837.58 per share, totaling approximately $443,917. The transaction follows a period of significant stock appreciation, with CASY trading near $823, marking a 58% gain over the past year and a 49% year-to-dat…
Stephen P. Bramlage Jr., Chief Financial Officer of Casey's General Stores Inc. (NASDAQ:CASY), sold 5,700 shares of the company's common stock on July 8, 2026, for approximately $4.78 million at a price of $838.16 per share. The transaction occurs as the stock has delivered a 58% return over the past year, currently trading at $823.12 with a market…
Koschel Williams Ena, Chief Operating Officer at Casey’s General Stores Inc. (NASDAQ:CASY), executed a sale of 2,800 shares on July 9, 2026, totaling approximately $2,334,332 at $833.69 per share. The transaction reduces her direct holdings to 21,969 shares, while she retains 419 indirect shares via a 401k plan and multiple restricted stock units (…
Robert George Culp IV, President and CEO of Culp Inc. (NYSE:CULP), executed a direct purchase of 2,768 shares on July 9, 2026, valued at $9,217. The transaction, priced at $3.33 per share, was facilitated through the company's 401(k) plan administrator. This acquisition brings Mr. Culp's total direct ownership to 424,795 shares, including holdings …
UroGen Pharma Ltd. (NASDAQ: URGN) Chief Medical Officer Mark Schoenberg completed a $400,000 liquidation of 10,000 ordinary shares on July 9, 2026. The transaction, executed at a weighted average price of $40.00 per share, marks the conclusion of a Rule 10b5-1(c) trading plan established on August 15, 2025. This sale occurs as URGN trades near its …
Michael James Hogan, serving as the Chief Strategy Officer at GLOBALFOUNDRIES Inc. (NASDAQ:GFS), has executed a series of share divestments totaling $180,430. The transactions, conducted on July 8 and July 9, 2026, were carried out under the framework of a Rule 10b5-1 trading plan. This strategic exit coincides with a period of substantial market p…
